Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy

Nanjing Medical University

Status

Enrolling

Conditions

Hepatocellular Carcinoma

Treatments

Procedure: hypovolemic phlebotomy

Study type

Interventional

Funder types

Other

Identifiers

NCT05887661

2022-SR-102

Details and patient eligibility

About

The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are:

The safety and feasibility of HP
To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of Hepatocellular Carcinoma
Preference for laparoscopic hepatectomy and patient agreement

Exclusion criteria

Age <18 years
Pregnancy
Refusal of blood product transfusion
Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
History of significant cerebrovascular disease
Restrictive or obstructive pulmonary disease
Uncontrolled hypertension
Renal dysfunction (glomerular filtration rate <60 mL/min),
Hemoglobin <100 g/L
Abnormal coagulation values (international normalized ratio >1.5 not on warfarin and/or platelet count <100 ×109/L)
Evidence of hepatic metabolic disorder (bilirubin >35 mmol/L)
Presence of active infection
Preoperative autologous blood donation
Patients were not allowed to receive erythropoietin at any time during the index hospitalization.